AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04082676
Drug: Hyperbaric bupivacaine spinal
RxNorm normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In this group will receive intrathecal hyperbaric bupivacaine based on patients height (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)
Trial: NCT00143520
Drug: Rivoglitazone
RxNorm normalized name: Rivoglitazone
DrugBank: Rivoglitazone (DB09200)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00143520
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01104337
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets twice a day along with two matching placebo tablets once daily
Trial: NCT01104337
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets three times a day
Trial: NCT00513474
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan 3.2 mg/kg/day from day -7 to day -4 as standard of care for myeloablative (bone marrow depletion) conditioning at the investigator's discretion
Trial: NCT00333307
Drug: recombinant human relaxin
RxNorm normalized name: Recombinant human relaxin
DrugBank: Serelaxin (DB05794)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01400633
Drug: decitabine injection
RxNorm normalized name: decitabine Injection
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
Trial: NCT00629642
Drug: Solifenacin Succinate
RxNorm normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, 10mg
Trial: NCT00629642
Drug: Solifenacin Succinate
RxNorm normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, 5mg
Trial: NCT00629642
Drug: Oxybutynin Hydrochloride
RxNorm normalized name: Oxybutynin hydrochloride
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, 15mg
Trial: NCT00777673
Drug: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eligible patients will receive:~* nab-paclitaxel IV on days 1, 8, and 15. Treatment will be repeated every 28 days 28 days for 4 courses.~* Carboplatin IV on day 1. Treatment will be repeated every 28 days for 4 courses.~* Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 4 courses.~After completion of the above regimen, patients will receive:~* Doxorubicin IV on day 1. Treatment will be repeated every 14 days for 4 courses.~* Cyclophosphamide IV on day 1. Treatment will be repeated every 14 days for 4 courses.~* Bevacizumab IV on day 1. Treatment will be repeated every 14 days for 2 courses.~Patients will then proceed with:~- Surgery including axillary staging~A minimum of 4 weeks post operatively, patient will receive:~- Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 8 courses.
Trial: NCT01447472
Drug: MDMA
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single dose of MDMA ( 1.5 mg/kg; range: 75-100 mg)
Trial: NCT00005021
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005021
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00005021
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04813874
Drug: Nitrous Oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous Oxide Inhalational Agent
Trial: NCT02656342
Drug: D-Cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Predicted to enhance stabilization of the effects of concentrated exposure treatment
Trial: NCT02046200
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin is a semi-synthetic macrocyclic lactone used worldwide as a broad-spectrum antiparasitic avermectin.
Trial: NCT02046200
Drug: Alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03156452
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg and 250mg tablets for oral administration
Trial: NCT02417337
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01482286
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.
Trial: NCT00224354
Drug: ONTAK
RxNorm normalized name: Ontak
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: an interleukin-2 immunotoxin directed to the CD25 antigen (denileukin diftitox, ONTAK
Trial: NCT00674232
Drug: 600 mcg misoprostol
RxNorm normalized name: misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose of misoprostol taken orally
Trial: NCT00098293
Drug: Maraviroc + Zidovudine/Lamivudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Trial: NCT00098293
Drug: Efavirenz + Zidovudine/Lamivudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Trial: NCT00098293
Drug: Maraviroc (UK-427,857) + Zidovudine/Lamivudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Trial: NCT03400943
Drug: Vilaprisan (BAY1002670)
RxNorm normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of Vilaprisan once daily up to 2 x 12 weeks
Trial: NCT00331149
Drug: Ropinirole prolonged release
RxNorm normalized name: ropinirole Extended Release Oral Tablet
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00331149
Drug: ropinirole immediate release
RxNorm normalized name: ropinirole Extended Release Oral Tablet
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03518203
Drug: Eculizumab
RxNorm normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eculizumab will be administered as intravenous infusion (IV) over 60 minutes. The dosage form will be 300 mg single-use vials each containing 30 mL of 10 mg/mL sterile, preservative-free solution.
Trial: NCT02829957
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10mg BID for 7 days, then 5mg BID for three months
Trial: NCT02829957
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15mg BID for 7 days, then 20mg daily for three months
Trial: NCT02449928
Drug: sodium lactate Ringer's injection(Baxter, ShangHai, China)
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: use sodium lactate Ringer's injection to resuscitate the septic shock patients(lactate group)
Trial: NCT02449928
Drug: Compound Sodium Chloride Injection (CR Double-Crane, Beijing, China)
RxNorm normalized name: China-Gel
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: use Compound Sodium Chloride injection to resuscitate the septic shock patients(control group)
Trial: NCT01623284
Drug: C-11 PiB
RxNorm normalized name: C-11 PiB
DrugBank: Pittsburgh Compound B (DB15161)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time intravenous administration of 740 megabecquerel (MBq) of \[N-methyl-11C\]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
Trial: NCT00560404
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120, 200 or 360 micrograms sc monthly (starting dose)
Trial: NCT00560404
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT03019588
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT05282407
Drug: Tenofovir disoproxil 245mg
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet q.d. for 48 weeks
Trial: NCT05282407
Drug: Tenofovir disoproxil fumarate 300mg
RxNorm normalized name: TENOFOVIR DISOPROXIL FUMARATE 300MG TAB
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet q.d. for 48 weeks
Trial: NCT01084135
Drug: Rivastigmine
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. Subjects receiving placebo will maintain the same schedule. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
Trial: NCT01155310
Drug: Helium/Oxygen 78%/22%
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices.
Trial: NCT01155310
Drug: Air/Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices.
Trial: NCT00002461
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002461
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002461
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04005365
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: add propranolol in gastric cancer patients who need to receive preoperate chemotherapy
Trial: NCT02657551
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes.
Trial: NCT05358912
Drug: Vasopressor Agent
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive vasopressor agents according to Surviving Sepsis Campaign Guidelines 2021
Trial: NCT05358912
Drug: Crystalloid Solutions
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive crystalloid solutions according to Surviving Sepsis Campaign Guidelines 2021
Trial: NCT00015340
Drug: Buprenorphine/naloxone
RxNorm normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01666080
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.4 mg/kg (0.5 mg/kg if \<4 years of age) intravenously (IV) every 6 hours on Days -8 and -7.
Trial: NCT01666080
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/m\^2 intravenously (IV) over 1 hour on days -6 through -2.
Trial: NCT01666080
Drug: Keppra
RxNorm normalized name: Keppra
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Keppra will be given for seizure prophylaxis during busulfan administration as per the standard institutional protocol.
Trial: NCT01206270
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate 1000mg (in 4 ml of castor oil injections) at baseline (0-week), 6-week, 18-week, 30-week
Trial: NCT01206270
Drug: Castor Oil
RxNorm normalized name: Castor Oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of Castor Oil injected at baseline (0-week), 6-week, 18-week, 30-week.
Trial: NCT03784300
Drug: 50 mg PTI-125
RxNorm normalized name: PTI-110
DrugBank: PTI-110 (DB18298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTI-125 50 mg Oral Solution
Trial: NCT03784300
Drug: 100 mg PTI-125
RxNorm normalized name: PTI-110
DrugBank: PTI-110 (DB18298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTI-125 100 mg Oral Solution
Trial: NCT03784300
Drug: 200 mg PTI-125
RxNorm normalized name: PTI-110
DrugBank: PTI-110 (DB18298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTI-125 200 mg Oral Solution
Trial: NCT04381377
Drug: azoximer bromide
RxNorm normalized name: Azoximer bromide
DrugBank: Azoximer bromide (DB15689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational medicinal product
Trial: NCT01602666
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01602666
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01602666
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00006215
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00006215
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02416388
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy :~Idarubicin 9mg/m² /day, from D1 to D5 (IV, 30min)~+ cytarabine 200mg/m²/day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate \< 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L).
Trial: NCT02416388
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction chemotherapy :~Daunorubicin 90mg/m²/day, from D1 to D3 (IV, 30min)~+ cytarabine 200mg/m² /day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate \< 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L).
Trial: NCT02416388
Drug: HD Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Consolidation chemotherapy course (s) :~-High dose cytarabine: 3g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group
Trial: NCT02416388
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GvHD prophylaxis post allogeneic SCT :~-Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100
Trial: NCT02416388
Drug: vosaroxin
RxNorm normalized name: vosaroxin
DrugBank: Vosaroxin (DB11999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation chemotherapy course (s) :~-70 mg/m² on D1 and D4
Trial: NCT02416388
Drug: ID cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Consolidation chemotherapy course (s) :~-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group
Trial: NCT02416388
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Consolidation chemotherapy course (s) :~-10 mg/12h on D1, D3 and D5
Trial: NCT02416388
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Consolidation chemotherapy course (s) :~Once RP2D has been determined from the results of the dose selection phase (phase 1), the optimal dose level retained for randomized phase 2 will be one of the following:~* 100 mg/d on D1 to D8 (selection phase dose level 1)~* or 200 mg/d on D1 to D8 (selection phase dose level 2)~* or 400 mg/d on D1 to D8 (selection phase dose level 3)~* or 400 mg/d on D1 to D14 (selection phase dose level 4)
Trial: NCT02784444
Drug: MSDC-0602K
RxNorm normalized name: MSDC-0160
DrugBank: Mitoglitazone (DB11721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSDC-0602K capsules
Trial: NCT00513474
Drug: cyclosporin-A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin-A as standard of care for GVHD prophylaxis at the investigator's discretion
Trial: NCT01087489
Drug: 4% lidocaine
RxNorm normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The eye will be topically anesthetized with 0.5% proparacaine drops and 4% lidocaine drops and a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface followed in three rounds by additional 5% povidone iodine and a sterile cotton swab soaked in sterile 4% lidocaine applied with gentle pressure to the area designated for injection in the infero-temporal quadrant.
Trial: NCT01316900
Drug: tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18 mcg once-daily
Trial: NCT01290354
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Unlabelled, administered orally
Trial: NCT01290354
Drug: [11C] lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Radiolabelled, administered intravenously
Trial: NCT00693732
Drug: Escitalopram treatment
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On study inclusion at Visit 2, patients will be successively randomised using a computer generated randomisation list to either placebo or escitalopram (Lundbeck Export A/S, Singapore) 10mg given at bedtime in the first 2 weeks, followed by 20mg in the next 6 weeks. The treatments will be identical in appearance and will be administered in double-blind fashion. Treatment with any anticoagulants, antidiabetics, antimigraine drugs, antispasmodics, analgesics, psychoactive agents including antidepressants, Zelmac®, TCM or acupuncture for IBS and any drugs affecting nociception as judged by investigator are prohibited during the entire study.
Trial: NCT00513474
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide as standard of care for myeloablative conditioning at the investigator's discretion
Trial: NCT00890097
Drug: AL-8309B Ophthalmic Solution
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00890097
Drug: AL-8309B Vehicle
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredients used as placebo comparator
Trial: NCT00398450
Drug: azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02713841
Drug: sc insulin lispro (LIS)
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: insulin lispro administered subcutaneously
Trial: NCT00289900
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01703221
Drug: Omarigliptin
RxNorm normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
Trial: NCT01703221
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin 50 mg tablet administered orally once daily